Prostate Cancer | Specialty

Advancements in Nonmetastatic CRPC

July 31st 2019

Dr. Tan Discusses the FDA Approval of Darolutamide in M0CRPC

July 31st 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the FDA approval of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer (M0CRPC).

FDA Approves Darolutamide for Nonmetastatic CRPC

July 31st 2019

The FDA has approved darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on the Role of PSA in Early Detection of Prostate Cancer

July 30th 2019

Leonard G. Gomella, MD, discusses the role of prostate-specific antigen screening in the early detection of prostate cancer.

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

July 26th 2019

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Dr. Vaena on Major Advances in Metastatic Prostate Cancer

July 26th 2019

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

Dr. Yu on Future Directions in Prostate Cancer

July 25th 2019

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.

Pivotal Trials Propel Progress in Prostate Cancer

July 24th 2019

Celestia S. Higano, MD, FACP, shares insight on key trials in prostate cancer.

Dr. Choudhury on the Use of Radiopharmaceuticals in Prostate Cancer

July 24th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of radiopharmaceuticals in the treatment of patients with prostate cancer.

Dr. McGregor on the Goals of ADT in Prostate Cancer

July 23rd 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.

Dr. Lee Highlights Key Takeaways From SPARTAN Trial in M0CRPC

July 20th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, highlights key takeaways from the phase III SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Tagawa on Significance of BRCA2 With PSMA-Targeted Radionuclide Therapy in Prostate Cancer

July 17th 2019

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

Dr. Higano on the GETUG-AFU 16 Trial Results in Prostate Cancer

July 17th 2019

Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.

Dr. Magi-Galluzzi on Preventing Overtreatment of Prostate Cancer

July 15th 2019

Cristina Magi-Galluzzi, MD, PhD, discusses the importance of properly diagnosing patients with prostate cancer to avoid overtreatment.

Enzalutamide Could Have Pivotal Role in Metastatic Hormone-Sensitive Prostate Cancer

July 12th 2019

Christopher Sweeney, MBBS, discusses the results of the ENZAMET trial and the next steps for researching the efficacy of enzalutamide in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Yu on Rationale for the KEYNOTE-365 Study in mCRPC

July 9th 2019

Evan Y. Yu, MD, discusses the rationale behind the KEYNOTE-365 trial, looking at pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Lead Investigator Highlights Apalutamide Efficacy in Metastatic Castration-Sensitive Prostate Cancer

July 1st 2019

Kim Chi, MD, discusses how the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.

Dr. Choudhury on Targeted Therapy in Prostate Cancer

June 28th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

Dr. McGregor on the Goal of the PRONOUNCE Trial in Prostate Cancer

June 28th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the hope for the phase IIb PRONOUNCE trial in prostate cancer.

Update Shows Depth of Darolutamide Benefit in Nonmetastatic CRPC

June 27th 2019

Karim Fizazi, MD, PhD, discusses the impact of darolutamide on pain progression and quality of life in patients with nonmetastatic castration-resistant prostate cancer.